The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.
 
Yesung Lee
No Relationships to Disclose
 
Natasha Masub
No Relationships to Disclose
 
Todd Wechter
No Relationships to Disclose
 
Judy Zhong
No Relationships to Disclose
 
Una Moran
No Relationships to Disclose
 
Farbod Darvishian
No Relationships to Disclose
 
David Polsky
Honoraria - MoleSafe
Consulting or Advisory Role - DermTech; MolecularMD; Novartis
Patents, Royalties, Other Intellectual Property - Royalty payments for patented methods to detect circulating mutant BRAF DNA; Royalty payments for patented methods to detect circulating mutant BRAF DNA (Inst)
 
Russell S. Berman
No Relationships to Disclose
 
Richard L. Shapiro
No Relationships to Disclose
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Iman Osman
No Relationships to Disclose
 
Anna C. Pavlick
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst); Millennium (Inst)
 
Melissa Wilson
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb